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In Vaidya’s response to Hepel and Wazer1, Figure 1 illustrates how the upper confidence limit for the 
difference between treatment outcomes allows assessment of non-inferiority in a trial2. This follows FDA 
guidelines3. It is imperative however that the underlying statistical analysis method and associated 
confidence limit are appropriate to the event of interest and the completeness of data. It is 
disappointing, therefore, that the TARGIT trialists persist in using a non-inferiority test statistic based on 
binomial proportions. Binomial analysis simply divides the number of recurrences by the total number of 
patients; thus subjects with one month or 5 years’ follow-up contribute the same to the denominator. 
Moreover, subjects with very short follow-up are counted as not having had a LR. This is flawed as 
shown by a simple example. Assume two groups of 30 patients with long follow-up and 10 and 20 
failures respectively: a statistically significant (P=0.01) difference of 33% in failure rates is observed. 
Adding 200 cases with very short follow-up to each group (contributing no additional failures), the 
difference in failure rates is now only 4% and no longer significant. In TARGIT-A fewer than 700 patients 
have at least 5 years’ follow-up or an observed LR – i.e. have the full information required for a binomial 
analysis. In contrast, survival analysis methods use all available data, account for varying follow-up and 
timing of events, and incorporate censoring (a subject without an event at the time of last contact has a 
risk of failing in the future). The TARGIT trialists argue that their assessment is better because it uses all 
recorded events, in contrast to the “single snapshot point estimates of 5-year recurrence rates” 
obtained from Kaplan-Meier (K-M) analysis – revealing a fundamental misunderstanding of survival 
analysis.  
 
Appropriate assessment of non-inferiority in the TARGIT-A trial would employ survival analysis to 
estimate the absolute difference in 5-year recurrence rates (protocol-specified primary endpoint), with a 
confidence interval (CI). The upper confidence limit would indicate whether or not the pre-specified 
threshold for non-inferiority had been crossed. Survival analysis provides a hazard ratio (HR) calculated 
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using all reported events, which can be applied to any time-specific rate to obtain an estimate of the 
difference in event rates between treatment groups (with CI)4. As the relevant figures were not 
presented in the TARGIT-A Lancet 2014 paper5, it was previously necessary to estimate them indirectly 
from the information provided to establish an estimate which accounted for the variability in both 
treatment groups and not just TARGIT6,7. The TARGIT trialists can and should provide a proper analysis of 
LR rates at 5 years (with CI), to enable an unequivocal assessment of non-inferiority.  
 
Vaidya’s citation of Cuzick8 reflects a fundamental misunderstanding of 1-sided versus 2-sided CIs as 
calculation of the upper limit of a 2-sided 90%CI provides the same limit of a 1-sided 95%CI. Vaidya 
confirms that the significance level set for the primary outcome changed from 5% in the protocol to 1% 
for the final analyses; therefore should assessment of non-inferiority not be based on the higher 1-sided 
99%CI?   
 
Another major misunderstanding is to state that predefined strata are not subgroups.  P-values are 
designed for a single predefined hypothesis, and should not be applied to separate subgroups/strata 
without a Bonferroni correction. The TARGIT protocol clearly states that the main analysis will include all 
randomised patients and the focus on the pre-pathology subgroup was clearly post-hoc after seeing the 
results. The dangers of restricting results to subgroups are well-known9. 
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